What is known and objective: Proactive synchronization of medication refills through an appointment-based model (ABM) is a community pharmacy-based intervention targeting adherence to medications. We aimed to systematically review evidence on the impact of the ABM on medication taking behaviour, health resource utilization, clinical outcomes and the preferences of patients and providers. 
| WHAT IS KNOWN AND OBJECTIVE
According to a national survey, the majority of Americans 40 years of age or older report at least one non-adherent medication taking behaviour on average, within the prior 12 months. 1 The most common behaviour leading to non-adherence was missing a dose, followed by forgetting to take the medication, failing to refill a prescription on time, taking a lower dose, not filling a new prescription and stopping the medication all together. This is consistent with prior data which suggests medication non-adherence as multifactorial involving individual patient characteristics, patient beliefs and attitudes, health literacy, access and costs. 2, 3 Thus, multifaceted interventions to target medication non-adherence are recommended.
2,3
The appointment-based model (ABM) is one intervention that aims to improve medication adherence by proactively synchronizing medication refills allowing patients to pick up their months' supply of medication in one trip. 4 The concept of proactive, synchronized refills is termed "medication synchronization" and is a core component of the ABM. 5 Prior to the pickup appointment, the pharmacist calls the patients to review the refill list and any medication changes that have occurred since the prior appointment. Through the ABM, the pharmacy staff have the opportunity to review the complete medication list and communicate with prescribers prior to filling the medications should modification in the regimen be indicated. Pharmacist may also engage the patient in additional services to optimize patient care, including medication therapy management (MTM). Thus, although the ABM is focused on improving medication adherence, it has potential to impact patient health outcomes beyond adherence.
We aimed to conduct a systematic review to identify and synthesize evidence on the impact of ABMs on medication taking behaviour, health resource utilization, clinical outcomes and the preferences of patients and providers.
| METHODS

| Search strategy
We conducted a systematic literature search of MEDLINE and Scopus from database inception through 6 February 2017. Our search was limited to English-language publications and used terminology describing medication synchronization, the ABM or community pharmacy services. To augment our bibliographical database search, we reviewed the first 500 results of a Google Scholar search using the terms "medication synchronization" and "appointment-based model" separately and we also performed backwards citation tracking of included studies. 
| Study selection
| Data collection
Using a standardized data collection form, two investigators independently collected the following data from included studies: first author's last name, publication year, sample size, study design, followup duration, pharmacy setting and geographic region, demographics of the enrolled population, ABM characteristics (eg refill cycle length, commercial programme implemented), reported outcomes and corresponding results and data necessary to evaluate the risk of bias. In the event that an outcome was reported at multiple time points, we included the data consistent with the longest duration of follow-up.
| Internal validity assessment
To assess the internal validity of included studies, the NewcastleOttawa Scale (NOS) and the Cochrane Collaboration risk of bias tool was used for observational and randomized studies, respectively. 6, 7 The NOS evaluates eight items within the domains of selection, comparability and outcomes. Studies meeting satisfactory criteria were awarded a star (*) for each of the eight items; otherwise a minus (−) sign was given. The Cochrane Collaboration tool included seven sources of bias within six domains (selection, performance, detection, attrition, reporting or other bias). Each source of bias was determined to be of low, high or unclear risk using the guidance provided by the tool. Internal validity was assessed for each study by two separate investigators with conflicts resolved through discussion. T A B L E 1 (Continued)
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| RESULTS
Our bibliographical database search identified 3322 citations with
an additional citation identified through Google Scholar ( Figure 1 ).
After screening and full-text assessment, five studies were included in our review and an overview of their characteristics are presented in Table 1 . [8] [9] [10] [11] [12] [13] DiDonato et al. 8 used a randomized, controlled trial design to compare medication synchronization, patient education and usual care over a 4-month period. This trial was specific to hypertensive patients and targeted the clinical outcome of blood pressure in addition to self-reported questionnaire to measure adherence. Three studies [9] [10] [11] were observational in design and compared patients who participated in an ABM to those who did not, amongst users of select chronic medication classes. Matching or multivariate regression was employed to control for confounding.
All three studies 9-11 evaluated objective measures of medication taking behaviour at 12 months. Additionally, one of these observational studies 9 also evaluated healthcare resource utilization and costs at 12 months, whereas a second study 11 used outcomes data to model costs using a decision-tree analysis. Finally, a single survey-based study 12 assessed patient satisfaction with ABM after ≥3 months of the intervention.
All included studies were performed in the midwestern United
States and were primarily within chain pharmacies. Aside from the randomized trial, patients self-selected into the ABM service. Patients were primarily in the upper 40s to lower 70s in age, and both genders were represented well. Consistent with our inclusion criteria, all studies employed the ABM. Patients received a call to confirm medications to be refilled prior to each refill cycle, which in most studies was monthly although one study allowed patients to select their cycle length. In three studies, 8, 10, 12 patients picked up their medications inperson while options inclusive of in-person pickup or mail order were used in the remaining two studies. The study by Zillich et al. 9 also included telephonic MTM services and distinct medication packaging inclusive of over-the-counter medications and vitamins, as part of the intervention. MTM services are suggested to be incorporated into ABM although is not required. 
| Internal validity assessment
Four studies were non-randomized and their internal validity assessment suggests a low risk of bias for these studies (Table 2 ).
9-12
Three observational studies [9] [10] [11] were satisfactory in all domains except in demonstration that the outcome of interest was not present at the start of the study. The fourth study by Butler and colleagues 12 used patient self-reported data and thus was deemed to be of lower quality in this domain and given the single cohort design, the domains regarding selection and comparability of cohorts were not applicable.
The single randomized trial 8 was assessed as having a high risk of bias in four of seven domains because of the methods used for randomization and lack of blinding of investigators or participants. T A B L E 2 Internal validity assessment results. Studies assessed by the modified Newcastle-Ottawa Scale were given a (*) or minus sign (−) with each item if they were determined to have high or low quality, respectively; studies assessed by the Cochrane Collaboration risk of bias tool were given a positive (+) or minus (−) sign or question mark (?) if they were determined to have low, high or unclear risk of bias, respectively. NA, not applicable 
| Evaluation of outcomes
| Impact on medication taking behaviour
Three observational studies measured medication taking behaviours objectively (Table 3 ), all at 12 months. [9] [10] [11] The ABM was associated with a 2-to 6-fold increase in adherence after adjustment for confounding factors and regardless of the pharmacologic class analysed.
Adherence was defined as having a proportion of days covered (PDC)
at or above 80%. Evaluation of PDC as a continuous variable found similar associations; the PDC was significantly increased for prescriptions where patients were participating in medication synchronization vs control. In the one study 9 Lastly, self-reported medication compliance after ≥3 months of participation in an ABM collected in a survey-based study 12 found patient to "agree" that they were more compliant with their medications since participating in the programme (mean±SD 4.1±1.0 on a 5-point Likert scale).
| Impact on clinical outcomes, resource utilization and costs
A single trial 8 evaluated the impact of medication synchronization on clinical outcomes, specifically the impact on measures of blood pressure at 4 months. Patients were randomized into one of three arms:
ABM, patient education and control, and there was a statistically significant reduction in systolic blood pressure (SBP) of 4, 10 and 9 mm
Hg, within each arm, respectively, comparing baseline to 4 months. 
T A B L E 3 (Continued)
However, the difference in SBP change across arms was not evaluated. Diastolic blood pressure (DBP) was significantly reduced by 3 mm Hg in the control arm from baseline to 4 months, although
was not significantly changed in the ABM or patient education arms.
Again, no comparison in the change of DBP across groups was made.
A significantly higher proportion of patients were considered to be One study 9 evaluated resource utilization and costs, comparing patients who participated in medication synchronization in combination with distinct prescription packaging and telephonic MTM to a control cohort. There was no significant association between the combined intervention and either all-cause emergency department (ED) visits or all-cause hospitalizations at 12-months (Table 4) . Findings were similar when only ED visits or hospitalizations that were related to outpatient sensitive conditions were analysed. The combined intervention was associated with a significant increase in adjusted total costs relative to control, by 84%. This was driven by increases in the individual outcomes of outpatient costs and pharmacy costs, by 12%
and 50% relative to control, respectively. There were no significant differences in inpatient and ED costs between the intervention and control cohorts.
A decision-tree analysis 13 utilizing effectiveness data from Holford et al. 10 was published separately. Several medication classes ultimately representing three disease states, hypertension, diabetes and hyperlipidaemia, were incorporated into the 1-year model. Savings per additional dollar spent on drugs over a 1-year period for participants of ABM vs usual community pharmacy care ranged from $1.25 with thiazides to $36.96 with metformin (Table 4) . ABMS, appointment-based medication synchronization; ACEI, angiotensin-converting enzyme inhibitor; aCR, adjusted cost ratio; aOR, adjusted odds ratio; ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; DBP, diastolic blood pressure; ED, emergency department; NR, not reported; SBP, systolic blood pressure; SD, standard deviation; US$, United States dollar; ∆, change. Multivariate logistic regression model adjusted for age, sex, ethnicity, marital status, county of residence, type of care management, total number of Elixhauser comorbidities and number of unique prescriptions taken during the 12-mo pre-index period, pre-index ED visit(s) and hospitalization(s). c Multivariate regression model adjusted for costs outcomes adjusted for age, sex, ethnicity, total number of Elixhauser comorbidities, number of unique prescriptions taken during the 12-mo pre-index period; pre-index ED visits and hospitalizations and pre-index medical and pharmacy costs, using Gamma distribution with a log-link function. Benefit-cost ratio calculated by taking total disease-specific direct medical costs saved due to improved medication adherence associated with ABMS divided by total medication costs added due to improved medication adherence associated with ABMS.
T A B L E 4 Impact of the appointment-based model on resource utilization and costs
| Impact on patient satisfaction
Only one study assessed patient satisfaction with medication synchronization, using questions on a Likert scale. The ABM also provides a patient-centred service that may serve as an entryway for additional advanced patient services. 5, 16, 17 Efficiencies gained in work flow and improved inventory control, benefits of medication synchronization reported by some programmes, 18 may be reallocated to allow pharmacists to engage in activities beyond dispensation. Such activities may include more consistent monthly and personalized interaction with the patient to strengthen the connectedness between a patient and their pharmacy staff and begin to address the dynamic and multifactorial causes of non-adherence. 16 Adherence management can subsequently provide opportunities for pharmacists to identify and resolve other drug therapy problems, in the context of MTM. Although non-adherence itself is considered a medication-related problem, starting with this level of patient service may serve as a means to identify those who could benefit from more rigorous medication therapy reviews and disease state management. clinical outcomes data, we additionally included costs and patient or provider satisfaction. We were also able to include the more recently published cost analysis and a large observational study published in 2012 that was omitted from the prior review. Our conclusions agree with those previously made with new information supporting the costbenefit of such programmes to the longer term care of patients with chronic conditions such as hypertension, diabetes and hyperlipidaemia.
Our analysis has several limitations that should be noted. First, we were unable to statistically pool data due to the limited amount of data reported per outcome and the heterogeneous nature of the populations and interventions studied. Although all programmes operated under what would be defined as an ABM, differences such as the extent beyond medication synchronization that were offered, duration of services and the actual disease states patients were being treated for. Given the limited amount of clinical data evaluated in this literature base, we were unable to provide a summative effect of ABM on clinical outcomes.
| WHAT IS NEW AND CONCLUSION
The ABM provides a unique, patient-centred service to improve medication adherence and appears to carry a cost-benefit associated with the treatment of certain chronic conditions. Future research is needed to determine the impact on final health outcomes.
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